Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice

Oncogene

Volumn 26, Issue 27, 2007, Pages 4009-4017

  Loffler, K A ^a   Biondi, C A ^a,d   Gartside, M G ^a,e   Serewko Auret, M M ^a   Duncan, R ^a   Tonks, I D ^a   Mould, A W ^a   Waring, P ^b,f   Muller, H K ^c   Kay, G F ^a   Hayward, N K ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^f GENENTECH INC   (United States)

Author keywords

Endocrine; Pancreas; Parathyroid; Pituitary; Thyroid

Indexed keywords

METHIONINE; RETINOBLASTOMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CANCER GENETICS; CANCER INHIBITION; CONTROLLED STUDY; DISEASE SEVERITY; GENE DELETION; GENE INTERACTION; GENE LOCUS; GENE MUTATION; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; MOLECULAR MECHANICS; MOUSE; NONHUMAN; ONSET AGE; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; THYROID TUMOR; TUMOR GROWTH;

ANIMALIA; MUS;

EID: 34250021066     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210163     Document Type: Article

References (31)

1. Agarwal SK, Novotny EA, Crabtree JS, Weitzman JB, Yaniv M, Burns AL et al. (2003). Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci USA 100: 10770-10775.
2. Bertolino P, Tong WM, Galendo D, Wang ZQ, Zhang CX. (2003). Heterozygous Men1 mutant mice develop a range of endocrine tumors minicking multiple endocrine neoplasia type 1. Mol Endocrinol 17: 1880-1892.
3. Biondi C, Gartside MG, Tonks I, Paterson C, Hayward N, Kay GF. (2002). Targeting and conditional inactivation of the murine Men1 locus using the Cre recombinase:loxP system. Genesis 32: 150-151.
4. Biondi CA, Gartside MG, Waring P, Loffler KA, Stark MS, Magnuson M et al. (2004). Conditional inactivation of the Men1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol Cell Biol 24: 3125-3131.
5. Busygina V, Suphapeetiporn K, Marek LR, Stowers RS, Xu T, Bale AE. (2004). Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. Hum Mol Genet 13: 2399-2408.
6. Casanovas O, Hager JH, Gee Hong Chun M, Hanahan D. (2005). Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. Oncogene 24: 6597-6604.
7. Chandrasekharappa S, Teh BT. (2003). Functional studies of the MEN1 gene. J Intern Med 253: 599-605.
8. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR et al. (1997). Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276: 404-407.
9. Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA et al. (2001). A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 98: 1118-1123.
10. Cryns VL, Thor A, Xu HJ, Hu SX, Wierman ME, Vickery Jr AL et al. (1994). Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 330: 757-761.
11. Dunn JM, Phillips RA, Becker AJ, Gallie BL. (1988). Identification of germline and somatic mutations affecting the retinoblastoma gene. Science 241: 1797-1800.
12. Gobl AE, Berg M, Lopez-Egido JR, Oberg K, Skogseid B, Westin G. (1999). Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism. Bioch Biophys Acta 1447: 51-56.
13. Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH. (1991). The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67: 293-302.
14. Heppner C, Bilimoria KY, Agarwal SK, Kester M, Whitty LJ, Guru SC et al. (2001). The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 20: 4917-4925.
15. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M et al. (2004). Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430: 797-802.
16. Herrera RE, Sah VP, Williams BO, Makela TP, Weinberg RA, Jacks T. (1996). Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol Cell Biol 16: 2402-2407.
17. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. (1992). Effects of an Rb mutation in the mouse. Nature 359: 295-300.
18. Jin S, Mao H, Schnepp RW, Sykes SM, Silva AC, D'Andrea AD et al. (2003). Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 63: 4204-4210.
19. Kaji H, Canaff L, Lebrun JJ, Goltzman D, Hendy GN. (2001). Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc Natl Acad Sci USA 98: 3837-3842.
20. Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, Xiong Y et al. (2005). Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and pl8INK4c. Proc Natl Acad Sci USA 102: 14659-14664.
21. Kim H, Lee JE, Cho EJ, Liu JO, Youn HD. (2003). Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res 63: 6135-6139.
22. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V et al. (1997). Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 6: 1177-1183.
23. Loffler KA, Biondi C, Gartside MG, Waring P, Stark MS, Serewko-Auret MM et al. (2006). Broad tumour spectrum in a mouse model of multiple endocrine neoplasia type 1. Int J Cancer Oct 16; [Epub ahead of print].
24. Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C, Koff A. (1999). p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci USA 96: 6382-6387.
25. Poisson A, Zablewska B, Gaudray P. (2003). Menin interacting proteins as clues towards the understanding of multiple endocrine neoplasia type 1. Cancer Lett 189: 1-10.
26. Ratineau C, Bernard C, Poncet G, Blanc M, Josso C, Fontaniere S et al. (2004). Reduction of menin expression enhances cell proliferation and is tumorigenic in intestinal epithelial cells. J Biol Chem 279: 24477-24484.
27. Schnepp RW, Mao H, Sykes SM, Zong WX, Silva AC, La P et al. (2004). Menin induces apoptosis in murine embryonic fibroblasts. J Biol Chem 279: 10685-10691.
28. Sowa H, Kaji H, Canaff L, Hendy GN, Tsukamoto T, Yamaguchi T et al. (2003). Inactivation of menin, the product of the multiple endocrine neoplasia type 1 gene, inhibits the commitment of multipotential mesenchymal stem cells into the osteoblast lineage. J Biol Chem 278: 21058-21069.
29. Sowa H, Kaji H, Hendy GN, Canaff L, Komori T, Sugimoto T et al. (2004). Menin is required for bone morphogenetic protein 2-and transforming growth factor beta- regulated osteoblastic differentiation through interaction with Smads and Runx2. J Biol Chem 279: 40267-40275.
30. Tonks ID, Hacker E, Irwin N, Muller HK, Keith P, Mould A et al. (2005). Melanocytes in conditional Rb-/- mice are normal in vivo but exhibit proliferation and pigmentation defects in vitro. Pigment Cell Res 18: 252-264.
31. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. (1994). Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 7: 480-484.